vs
PORTLAND GENERAL ELECTRIC CO（POR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
PORTLAND GENERAL ELECTRIC CO的季度营收约是Revvity的1.2倍（$889.0M vs $772.1M），Revvity净利率更高（12.7% vs 4.6%，领先8.1%），PORTLAND GENERAL ELECTRIC CO同比增速更快（7.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-142.0M），过去两年Revvity的营收复合增速更高（9.0% vs -2.2%）
波特兰通用电气（简称PGE）是财富1000强上市能源企业，总部位于美国俄勒冈州波特兰，业务覆盖发电、输电、配电全链路，为俄勒冈州近三分之二的工商业活动提供电力服务，受俄勒冈州公用事业委员会监管，前身为1888年成立的威拉米特瀑布电气公司。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
POR vs RVTY — 直观对比
营收规模更大
POR
是对方的1.2倍
$772.1M
营收增速更快
POR
高出2.0%
5.9%
净利率更高
RVTY
高出8.1%
4.6%
自由现金流更多
RVTY
多$303.8M
$-142.0M
两年增速更快
RVTY
近两年复合增速
-2.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $889.0M | $772.1M |
| 净利润 | $41.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 10.7% | 14.5% |
| 净利率 | 4.6% | 12.7% |
| 营收同比 | 7.9% | 5.9% |
| 净利润同比 | 7.9% | 3.9% |
| 每股收益（稀释后） | $0.36 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PORRVTY
| Q4 25 | $889.0M | $772.1M | ||
| Q3 25 | $952.0M | $698.9M | ||
| Q2 25 | $807.0M | $720.3M | ||
| Q1 25 | $928.0M | $664.8M | ||
| Q4 24 | $824.0M | $729.4M | ||
| Q3 24 | $929.0M | $684.0M | ||
| Q2 24 | $758.0M | $691.7M | ||
| Q1 24 | $929.0M | $649.9M |
净利润PORRVTY
| Q4 25 | $41.0M | $98.4M | ||
| Q3 25 | $103.0M | $46.7M | ||
| Q2 25 | $62.0M | $53.9M | ||
| Q1 25 | $100.0M | $42.2M | ||
| Q4 24 | $38.0M | $94.6M | ||
| Q3 24 | $94.0M | $94.4M | ||
| Q2 24 | $72.0M | $55.4M | ||
| Q1 24 | $109.0M | $26.0M |
毛利率PORRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率PORRVTY
| Q4 25 | 10.7% | 14.5% | ||
| Q3 25 | 18.3% | 11.7% | ||
| Q2 25 | 14.6% | 12.6% | ||
| Q1 25 | 18.1% | 10.9% | ||
| Q4 24 | 10.7% | 16.3% | ||
| Q3 24 | 15.7% | 14.3% | ||
| Q2 24 | 15.3% | 12.4% | ||
| Q1 24 | 17.4% | 6.8% |
净利率PORRVTY
| Q4 25 | 4.6% | 12.7% | ||
| Q3 25 | 10.8% | 6.7% | ||
| Q2 25 | 7.7% | 7.5% | ||
| Q1 25 | 10.8% | 6.4% | ||
| Q4 24 | 4.6% | 13.0% | ||
| Q3 24 | 10.1% | 13.8% | ||
| Q2 24 | 9.5% | 8.0% | ||
| Q1 24 | 11.7% | 4.0% |
每股收益（稀释后）PORRVTY
| Q4 25 | $0.36 | $0.86 | ||
| Q3 25 | $0.94 | $0.40 | ||
| Q2 25 | $0.56 | $0.46 | ||
| Q1 25 | $0.91 | $0.35 | ||
| Q4 24 | $0.34 | $0.77 | ||
| Q3 24 | $0.90 | $0.77 | ||
| Q2 24 | $0.69 | $0.45 | ||
| Q1 24 | $1.08 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $4.7B | — |
| 股东权益账面价值 | $4.1B | $7.3B |
| 总资产 | $13.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.13× | — |
8季度趋势，按日历期对齐
现金及短期投资PORRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务PORRVTY
| Q4 25 | $4.7B | — | ||
| Q3 25 | $4.7B | — | ||
| Q2 25 | $4.7B | — | ||
| Q1 25 | $4.7B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $4.4B | — | ||
| Q1 24 | $4.4B | — |
股东权益PORRVTY
| Q4 25 | $4.1B | $7.3B | ||
| Q3 25 | $4.0B | $7.4B | ||
| Q2 25 | $3.9B | $7.6B | ||
| Q1 25 | $3.8B | $7.6B | ||
| Q4 24 | $3.8B | $7.7B | ||
| Q3 24 | $3.6B | $7.9B | ||
| Q2 24 | $3.5B | $7.9B | ||
| Q1 24 | $3.5B | $7.8B |
总资产PORRVTY
| Q4 25 | $13.2B | $12.2B | ||
| Q3 25 | $13.0B | $12.1B | ||
| Q2 25 | $12.7B | $12.4B | ||
| Q1 25 | $12.7B | $12.4B | ||
| Q4 24 | $12.5B | $12.4B | ||
| Q3 24 | $11.9B | $12.8B | ||
| Q2 24 | $11.6B | $13.4B | ||
| Q1 24 | $11.6B | $13.4B |
负债/权益比PORRVTY
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.20× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 1.27× | — | ||
| Q1 24 | 1.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $148.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-142.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -16.0% | 21.0% |
| 资本支出强度资本支出/营收 | 32.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.61× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-71.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PORRVTY
| Q4 25 | $148.0M | $182.0M | ||
| Q3 25 | $403.0M | $138.5M | ||
| Q2 25 | $336.0M | $134.3M | ||
| Q1 25 | $231.0M | $128.2M | ||
| Q4 24 | $170.0M | $174.2M | ||
| Q3 24 | $244.0M | $147.9M | ||
| Q2 24 | $189.0M | $158.6M | ||
| Q1 24 | $175.0M | $147.6M |
自由现金流PORRVTY
| Q4 25 | $-142.0M | $161.8M | ||
| Q3 25 | $100.0M | $120.0M | ||
| Q2 25 | $99.0M | $115.5M | ||
| Q1 25 | $-128.0M | $112.2M | ||
| Q4 24 | $-222.0M | $149.8M | ||
| Q3 24 | $-9.0M | $125.6M | ||
| Q2 24 | $-109.0M | $136.6M | ||
| Q1 24 | $-150.0M | $129.7M |
自由现金流率PORRVTY
| Q4 25 | -16.0% | 21.0% | ||
| Q3 25 | 10.5% | 17.2% | ||
| Q2 25 | 12.3% | 16.0% | ||
| Q1 25 | -13.8% | 16.9% | ||
| Q4 24 | -26.9% | 20.5% | ||
| Q3 24 | -1.0% | 18.4% | ||
| Q2 24 | -14.4% | 19.7% | ||
| Q1 24 | -16.1% | 20.0% |
资本支出强度PORRVTY
| Q4 25 | 32.6% | 2.6% | ||
| Q3 25 | 31.8% | 2.6% | ||
| Q2 25 | 29.4% | 2.6% | ||
| Q1 25 | 38.7% | 2.4% | ||
| Q4 24 | 47.6% | 3.4% | ||
| Q3 24 | 27.2% | 3.3% | ||
| Q2 24 | 39.3% | 3.2% | ||
| Q1 24 | 35.0% | 2.7% |
现金转化率PORRVTY
| Q4 25 | 3.61× | 1.85× | ||
| Q3 25 | 3.91× | 2.97× | ||
| Q2 25 | 5.42× | 2.49× | ||
| Q1 25 | 2.31× | 3.03× | ||
| Q4 24 | 4.47× | 1.84× | ||
| Q3 24 | 2.60× | 1.57× | ||
| Q2 24 | 2.63× | 2.87× | ||
| Q1 24 | 1.61× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
POR
| Other | $507.0M | 57% |
| Commercial | $231.0M | 26% |
| Industrial | $140.0M | 16% |
| Direct Accesscustomers | $11.0M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
